Ignite Creation Date:
2024-05-06 @ 5:33 PM
Last Modification Date:
2024-10-26 @ 2:30 PM
Study NCT ID:
NCT05341583
Status:
RECRUITING
Last Update Posted:
2023-07-14
First Post:
2022-04-18
Brief Title:
Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase ALK Positive Non-small Cell Lung Cancer
Sponsor:
Organization:
Betta Pharmaceuticals Co Ltd